Abstract: The therapeutic benefits of cell therapies have been recognized for over 40 years by the scientific community. However, several barriers exist for cell therapies to enter the market and be commercially successful. These barriers include compliance to strict regulatory standards, complex logistics for products with a short shelf life, and expensive manufacturing procedures requiring large amounts of production space and costly manual labour. To overcome these challenges, Octane created the Cocoon™, an automated manufacturing platform capable of executing a fully closed and end-to-end production process. This seminar will explore the implementation of automated processes using the Cocoon manufacturing platform and its applications in industry.
Bio: Chris Miranda is a Business Development Analyst working at the Octane Group of Companies. He holds a BSc in Physics from McMaster University and an MSc in Physics from Memorial University. Prior to his work at Octane, Chris honed his skills in the life sciences industry as a Research Technician at Sunnybrook Health Sciences Centre and as an Operations Lead at the Centre for the Commercialization of Regenerative Medicine (CCRM). At Octane, Chris has worked in multiple departments: first, as a bioprocess development scientist where he investigated automated workflows for new orthopedic applications; and, most recently, as a Business Development Analyst where he has supported the Octane businesses through external funding partnerships and the identification of new strategic opportunities.